Barclays’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.76M | Sell |
70,987
-287,188
| -80% | -$6.84M | ﹤0.01% | 2427 |
|
|
2025
Q4 | $8.36M | Sell |
358,175
-14,717
| -4% | -$328K | ﹤0.01% | 1823 |
|
|
2025
Q3 | $7.35M | Buy |
372,892
+4,056
| +1% | +$83.4K | ﹤0.01% | 1913 |
|
|
2025
Q2 | $8M | Buy |
368,836
+170,755
| +86% | +$4.03M | ﹤0.01% | 1726 |
|
|
2025
Q1 | $4.8M | Sell |
198,081
-46,342
| -19% | -$1.04M | ﹤0.01% | 1951 |
|
|
2024
Q4 | $5.1M | Sell |
244,423
-4,035
| -2% | -$86.7K | ﹤0.01% | 2152 |
|
|
2024
Q3 | $4.94M | Buy |
248,458
+140,129
| +129% | +$2.6M | ﹤0.01% | 2106 |
|
|
2024
Q2 | $1.68M | Sell |
108,329
-32,472
| -23% | -$506K | ﹤0.01% | 2266 |
|
|
2024
Q1 | $2.24M | Sell |
140,801
-162,284
| -54% | -$2.45M | ﹤0.01% | 2467 |
|
|
2023
Q4 | $5.09M | Sell |
303,085
-27,821
| -8% | -$380K | ﹤0.01% | 2076 |
|
|
2023
Q3 | $3.87M | Sell |
330,906
-331,779
| -50% | -$4.44M | ﹤0.01% | 1491 |
|
|
2023
Q2 | $8.91M | Buy |
662,685
+468,846
| +242% | +$6.75M | 0.01% | 1037 |
|
|
2023
Q1 | $3.21M | Sell |
193,839
-97,614
| -33% | -$1.61M | ﹤0.01% | 1844 |
|
|
2022
Q4 | $5.42M | Buy |
291,453
+17,139
| +6% | +$264K | ﹤0.01% | 1569 |
|
|
2022
Q3 | $3.52M | Buy |
274,314
+269,506
| +5,605% | +$3.19M | ﹤0.01% | 1379 |
|
|
2022
Q2 | $34K | Sell |
4,808
-11,407
| -70% | -$83.7K | ﹤0.01% | 4191 |
|
|
2022
Q1 | $135K | Sell |
16,215
-101,645
| -86% | -$719K | ﹤0.01% | 3645 |
|
|
2021
Q4 | $797K | Buy |
117,860
+55,238
| +88% | +$363K | ﹤0.01% | 2966 |
|
|
2021
Q3 | $333K | Sell |
62,622
-86,216
| -58% | -$471K | ﹤0.01% | 3377 |
|
|
2021
Q2 | $857K | Sell |
148,838
-68,703
| -32% | -$355K | ﹤0.01% | 2756 |
|
|
2021
Q1 | $1M | Sell |
217,541
-36,947
| -15% | -$147K | ﹤0.01% | 2779 |
|
|
2020
Q4 | $849K | Sell |
254,488
-12,411
| -5% | -$41.7K | ﹤0.01% | 2873 |
|
|
2020
Q3 | $791K | Sell |
266,899
-11,456
| -4% | -$44.8K | ﹤0.01% | 2885 |
|
|
2020
Q2 | $1.29M | Buy |
278,355
+23,672
| +9% | +$106K | ﹤0.01% | 2528 |
|
|
2020
Q1 | $981K | Buy |
254,683
+141,623
| +125% | +$581K | ﹤0.01% | 2973 |
|
|
2019
Q4 | $424K | Buy |
113,060
+63,610
| +129% | +$297K | ﹤0.01% | 4435 |
|
|
2019
Q3 | $263K | Sell |
49,450
-12,743
| -20% | -$67.9K | ﹤0.01% | 4759 |
|
|
2019
Q2 | $239K | Buy |
62,193
+34,932
| +128% | +$151K | ﹤0.01% | 4951 |
|
|
2019
Q1 | $139K | Buy |
27,261
+26,127
| +2,304% | +$76.8K | ﹤0.01% | 5092 |
|
|
2018
Q4 | $2K | Sell |
1,134
-35,025
| -97% | -$100K | ﹤0.01% | 6696 |
|
|
2018
Q3 | $137K | Buy |
36,159
+29,093
| +412% | +$91.1K | ﹤0.01% | 5295 |
|
|
2018
Q2 | $22K | Sell |
7,066
-24,965
| -78% | -$75.7K | ﹤0.01% | 6124 |
|
|
2018
Q1 | $76K | Buy |
32,031
+18,562
| +138% | +$61.7K | ﹤0.01% | 5583 |
|
|
2017
Q4 | $52K | Sell |
13,469
-32,611
| -71% | -$108K | ﹤0.01% | 5730 |
|
|
2017
Q3 | $116K | Buy |
46,080
+30,001
| +187% | +$82.3K | ﹤0.01% | 4827 |
|
|
2017
Q2 | $44K | Buy |
+16,079
| New | +$33.6K | ﹤0.01% | 5426 |
|
|
2016
Q3 | – | Sell |
-7,986
| Closed | -$6K | – | 6621 |
|
|
2016
Q2 | $6K | Buy |
+7,986
| New | +$6.43K | ﹤0.01% | 5694 |
|
|
2016
Q1 | – | Sell |
-8,291
| Closed | -$17K | – | 6167 |
|
|
2015
Q4 | $17K | Buy |
8,291
+7,897
| +2,004% | +$22.6K | ﹤0.01% | 5238 |
|
|
2015
Q3 | $1K | Sell |
394
-1,047
| -73% | -$4.52K | ﹤0.01% | 6511 |
|
|
2015
Q2 | $6K | Buy |
+1,441
| New | +$5.74K | ﹤0.01% | 6339 |
|
Other funds holding CPRX
VCM
DM
VPM
Barclays's CPRX Position: Q1 2026 in Review
Barclays reduced its Catalyst Pharmaceutical (CPRX) stake by 80% in Q1 2026, selling an estimated $6.84M and leaving 70,987 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2427.
Barclays first reported a position in CPRX in Q2 2015 and has held it in 40 quarters since. The position peaked at $8.91M in Q2 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Barclays held 70,987 shares of Catalyst Pharmaceutical worth $1.76M as of Q1 2026.
- Barclays sold 287,188 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.84M.
- Catalyst Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2427 holding.
- Barclays first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 40 quarters since.
- Barclays's Catalyst Pharmaceutical position peaked at $8.91M in Q2 2023.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.